Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27956)	2/7/1999 10:19:00 AM
From: RXGOLF	Read Replies (8) \| Respond to of 32384

This morning I received some more information concerning off label drug use. Not only is it becoming more common, but the Pharmacist Letter disclosed in their Feb. 1999 letter that for the first time, the FDA will allow drug reps to give out information about UNAPPROVED uses of their prescription drugs. Until now, reps could only give out info about FDA-approved indications, even if the drug was commonly used"off-label". That is why we were never given info on verapamil for migraines,neurontin for neuropathic pain,Wellbutrin for ADD, etc., etc. Starting now, they can give out written info from articles in peer-reviewed,scientific, or medical journals. Greg